steadi
rise
number
immunocompromis
popul
due
increas
use
potent
immunosuppress
therapi
associ
increas
risk
acquir
fungal
opportunist
infect
immunocompromis
patient
account
high
morbid
mortal
rate
left
untreat
convent
antifung
drug
treat
fungal
diseas
mycos
increasingli
becom
inadequ
due
observ
vari
suscept
fungi
recurr
resist
rna
interfer
rnai
sequencespecif
gene
silenc
emerg
promis
new
therapeut
approach
chapter
discuss
variou
aspect
rnai
viz
fundament
rnai
machineri
present
fungi
silico
sirna
featur
design
guidelin
tool
sirna
deliveri
valid
gene
knockdown
therapeut
mycos
target
gene
identif
crucial
step
design
genespecif
sirna
addit
effici
deliveri
strategi
bring
effect
inhibit
fungi
subsequ
design
sirna
deliv
effect
vitro
either
soak
fungi
sirna
transform
invert
repeat
transgen
contain
plasmid
fungi
ultim
gener
sirna
final
fungal
inhibit
verifi
rna
protein
level
blot
techniqu
fluoresc
imag
biochem
assay
despit
challeng
sever
vitro
studi
spawn
optim
around
rnai
revolutionari
new
class
therapeut
mycos
pharmacokinet
paramet
need
evalu
vivo
studi
clinic
trial
recogn
rnai
novel
treatment
approach
mycos
last
two
decad
seen
rise
trend
immunocompromis
patient
richardson
krcmeri
warnock
richardson
ribe
et
al
heighten
risk
opportunist
fungal
infect
mycos
fungal
infect
affect
part
bodi
caus
superfici
mycos
affect
outermost
layer
skin
hair
cutan
mycos
extend
deeper
layer
skin
hair
nail
subcutan
mycos
involv
dermi
subcutan
tissu
muscl
fascia
system
mycos
dissemin
bodi
fungal
diseas
list
tabl
classifi
accord
three
import
phyla
fungal
taxonomi
ascomycet
basidiomycet
zygomycet
diseas
turn
sever
dissemin
common
immunosuppress
candidiasi
one
highli
frequent
fungal
infect
untreat
advanc
hiv
case
suffer
oropharyng
candidiasi
accord
world
health
organ
statist
anoth
studi
report
overal
mortal
rate
approxim
zygomycosi
ribe
et
al
invas
aspergillosi
highrisk
leukemia
patient
allogen
bone
marrow
transplant
patient
chamilo
kontoyianni
exist
fungal
treatment
requir
parallel
approach
involv
surgic
intervent
antifung
therapi
ribe
et
al
surgic
intervent
shown
improv
surviv
rate
mani
patient
surgeri
solut
treat
fungal
diseas
current
avail
antifung
drug
compris
polyen
macrolid
azol
drug
echinocandin
mukherje
et
al
among
polyen
amphotericin
b
firstlin
drug
choic
invas
mycos
ribe
et
al
drug
drawback
nephrotox
hepatotox
exhibit
liposom
amphotericin
b
narrow
spectrum
activ
shown
fluconazol
itraconazol
caus
problem
absorpt
pauw
picazo
moreov
fungi
acquir
resist
recurr
novel
antifung
agent
roger
either
due
defect
drug
import
efflux
drug
variat
intracellular
drug
process
alter
enzym
targetspecif
biosynthet
pathway
competit
inhibit
chamilo
kontoyianni
bhanderi
et
al
exist
treatment
effect
due
vari
suscept
fungi
toward
drug
henc
newer
safe
effect
therapeut
intervent
desir
report
use
gene
therapi
antisens
oligonucleotid
ribozym
dnazym
rnai
therapi
rnai
score
sever
benefit
techniqu
instanc
effect
deliveri
variou
organ
low
concentr
therebi
increas
safeti
costeffect
compar
proteinenzym
nonimmunogen
bypass
interferon
pathway
ruddon
gene
cosuppress
rnaityp
phenomenon
commonli
known
quell
fungi
first
discov
filament
fungu
neurospora
crassa
romano
macino
signific
aspect
rnai
establish
fire
mello
found
dsrna
time
effect
trigger
silenc
compar
ssrna
caenorhabd
elegan
fire
et
al
share
nobel
prize
medicin
physiolog
rnai
natur
occur
sequencespecif
gene
silenc
phenomenon
evolutionarili
highli
conserv
mechan
well
develop
eukaryot
organ
induc
doublestrand
small
noncod
rna
dsrna
rnamedi
gene
silenc
pathway
compar
thoroughli
known
establish
plant
anim
system
wide
investig
varieti
fungi
report
opportunist
pathogen
fungi
human
rnai
machineri
fungi
share
similar
mechanist
principl
organ
rnai
discov
consist
dsrna
precursor
dicer
enzym
risc
rnainduc
silenc
complex
target
mrna
dsrna
process
short
interf
rna
sirna
two
step
initi
step
effector
step
initi
step
dsrna
cleav
enzym
dicer
rnase
iii
famili
jinek
doudna
specif
length
nucleotid
effector
step
sirna
must
segreg
compet
singl
strand
guid
strand
guid
ribonucleotid
protein
complex
call
risc
siomi
siomi
member
argonaut
famili
protein
song
et
al
b
leuschner
et
al
fulci
macino
dicer
risc
complex
requir
atp
energi
argonaut
ntermin
domain
paz
domain
middl
domain
piwi
domain
guid
strand
incorpor
risc
nonincorpor
strand
known
passeng
strand
also
crucial
proper
target
mrna
cleavag
passeng
strand
cleav
ten
nucleotid
phosphat
guid
strand
target
mrna
cleavag
sever
impair
leuschner
et
al
cleav
target
mrna
util
rnadepend
rna
polymeras
rdrp
gener
dsrna
recogn
cleav
dicer
increas
number
sirna
molecul
scheper
gene
respons
rnai
discov
fungi
quell
first
rnai
gene
discov
n
crassa
encod
cellular
rdrp
simultan
clone
found
encod
argonaut
protein
partial
redund
dicer
protein
character
n
crassa
revers
genet
li
et
al
far
rnai
mechan
observ
saccharomyc
cerevisia
candida
guilliermondii
c
lusitania
c
tropicali
ustilago
maydi
otter
mannhaupt
scerevisia
attribut
absenc
conserv
compon
like
dicerlik
rnase
argonaut
piwilik
compon
rnadepend
rna
polymeras
howev
rnai
recent
discov
castellii
close
relat
scerevisia
also
c
albican
common
human
pathogen
david
p
bartel
lab
drinnenberg
et
al
found
speci
noncanon
dicer
activ
rnase
iii
domain
contain
gene
gener
sirna
gene
ortholog
rnase
iii
domain
argonautecontain
bud
yeast
mostli
enrich
long
invert
repeat
transpos
element
signific
facet
sirna
design
involv
identif
character
gene
target
play
key
role
surviv
organ
suppress
gene
inhibit
translat
limit
growth
fungu
particular
fungal
diseas
often
caus
one
fungu
instanc
zygomycosi
caus
rhizopu
absidia
mucor
rhizomucor
sirna
design
take
consider
conserv
antifung
drug
target
present
ubiquit
speci
drug
discoveri
process
becom
less
intric
crucial
point
taken
care
protein
correspond
gene
similar
human
genom
human
process
affect
instanc
cell
wall
promis
target
diseasecaus
fungi
pathway
format
cell
wall
readili
access
moussian
kegg
databas
http
wwwgenomejpkegg
refer
silenc
gene
code
signific
compon
cell
wall
biosynthesi
pathway
delimit
format
cell
wall
henc
restrain
growth
pathogen
fungu
instanc
studi
report
loss
cell
wall
polysaccharid
glucan
synthas
cell
wall
histoplasma
capsulatum
led
decreas
virul
pathogenesi
fungi
rappley
et
al
apart
cell
wall
target
carri
lipid
biosynthesi
pathway
translat
posttransl
level
previou
studi
led
confirm
nmyristoyl
transferas
lanosterol
demethylas
geranylgeranyl
transferas
potenti
drug
target
antifung
drug
benzofuran
azol
azaphilon
design
respect
kawasaki
et
al
song
et
al
singh
et
al
furthermor
ortholog
paralog
studi
perform
check
presenc
target
gene
relat
organ
highlight
evolutionari
histori
gene
inform
gene
conserv
acquaint
us
vital
relev
gene
sirna
perfect
complementari
match
target
mrna
henc
need
cautious
design
variou
comput
tool
freeli
avail
onlin
design
sirna
instanc
ambion
sirna
target
finder
eurofin
mwg
operon
free
onlin
design
tool
rnai
design
invitrogen
svm
rnai
sidesign
center
dharmacon
use
sirna
design
fungal
gene
design
sirna
molecul
pure
depend
suitabl
select
variou
sirna
featur
viz
sequenc
motif
gc
content
thermodynam
featur
etc
moreov
variou
studi
document
comparison
among
sirna
design
tool
yiu
et
al
matveeva
et
al
tool
mainli
follow
reynold
et
al
tuschl
et
al
guidelin
ration
sirna
design
usual
nucleotid
length
guidelin
describ
onward
section
accord
guidelin
region
within
bp
start
codon
termin
codon
intron
region
stretch
base
aaaa
cccc
region
gc
content
less
singlenucleotid
polymorph
repeat
low
complex
sequenc
avoid
mani
guidelin
design
sirna
propos
differ
group
mention
tuschl
et
al
provid
set
guidelin
commonli
known
mpi
principl
design
effect
sirna
initi
empir
rule
base
gc
content
symmetr
tt
overhang
effect
sirna
design
establish
tuschl
et
al
found
show
signific
proport
ineffect
sirna
describ
yiu
et
al
identifi
need
understand
structur
featur
sequenc
yiu
et
al
therefor
new
rule
suggest
advanc
technolog
effect
design
sirna
select
target
region
given
cdna
sequenc
begin
nt
downstream
start
codon
afterward
find
sequenc
motif
aa
n
sub
suitabl
sequenc
found
find
sequenc
motif
na
n
sub
convert
end
sens
sirna
tt
search
n
nucleotid
base
pair
adenin
r
adenin
guanin
purin
n
sub
thymin
cytosin
pyrimidin
nn
gc
content
must
around
target
sequenc
design
effici
sirna
molecul
ration
rule
set
total
eight
criteria
weight
valu
develop
experienti
analysi
silenc
effici
sirna
target
mrna
two
gene
reynold
et
al
dharmacon
inc
rulescriteria
cover
differ
composit
properti
sequenti
featur
individu
sirna
characterist
use
ration
sirna
design
algorithm
evalu
potenti
target
sequenc
assign
score
reynold
et
al
higher
valu
score
sequenc
reflect
higher
chanc
success
rnai
experi
tool
offer
dharmacon
inc
deploy
eight
criteriabas
ration
sirna
design
rule
guidelin
mauric
ho
et
al
develop
excelbas
templat
similar
guidelin
avail
http
sirna
clear
fig
differ
base
pair
show
differenti
stabil
respect
posit
h
c
u
despit
sever
silico
sirna
design
case
report
fungal
system
challeng
need
address
includ
optim
sirna
design
target
effici
deliveri
system
apart
genom
architectur
level
organiz
complex
exampl
wholegenom
duplic
event
commonli
observ
fungi
wapinski
et
al
dujon
et
al
ibrahim
et
al
rhizopu
oryza
give
rise
paralog
gene
might
nucleotid
sequenc
similar
activ
express
code
enzym
constraint
often
envisag
design
effect
sirna
fungal
enzym
target
one
mani
gene
given
enzym
target
nt
result
high
efficaci
silenc
yamada
et
al
silenc
one
three
gene
aspergillu
oryza
found
mere
silenc
suffici
enter
therapeut
phase
henc
design
common
sirna
gene
target
enzym
becom
arduou
task
chitin
synthas
wellaccept
antifung
drug
target
yet
use
design
sirna
r
oryza
genom
level
analysi
reveal
gene
encod
chitin
synthas
ibrahim
et
al
prospect
select
conserv
region
enzym
lucr
singl
sirna
might
effect
sever
fungi
caus
particular
diseas
enzym
present
exclus
fungi
henc
target
select
critic
toward
gene
natur
divers
sever
tool
avail
design
sirna
describ
tabl
siviru
effect
sirna
design
tool
sever
diverg
viral
genom
human
immunodefici
viru
hiv
hepat
c
viru
hcv
influenza
viru
sar
coronaviru
base
variou
sirna
design
guidelin
uitei
et
al
reynold
et
al
amarzguioui
prydz
offtarget
sirna
sequenc
identifi
use
sidirect
tool
predict
sirna
sequenc
sirna
conserv
region
genom
shown
inhibit
viral
replic
conclus
support
design
capac
tool
naito
et
al
rna
rule
set
javabas
program
predict
effici
sirna
design
basic
sirnarul
oper
two
score
sum
one
posit
rule
deduc
set
best
sirna
one
neg
rule
deduc
set
worst
sirna
rank
calcul
simpl
sum
two
valu
rule
weight
obtain
effici
algorithm
challeng
opensourc
commun
holen
dsir
tool
develop
vert
et
al
use
two
paramet
design
sirna
ie
positionspecif
thermodynam
stabil
nonpositionspecif
motif
format
composit
score
decid
fig
rel
stabil
end
sirna
adopt
reynold
et
al
sirna
better
lasso
regress
techniqu
also
provid
option
design
bp
sirna
effect
tool
compar
evalu
one
best
tool
matveeva
et
al
compar
tool
silico
sirna
design
follow
effici
deliveri
organ
choic
knockdown
target
gene
sirna
deliveri
strategi
employ
fungi
mainli
compris
soak
approach
use
chemic
synthes
sirna
insert
invert
repeat
transgen
irt
desir
plasmid
use
longhairpin
rna
lhrna
tabl
list
fungal
speci
strategi
perform
techniqu
employ
chemic
synthes
sirna
absorb
organ
briefli
involv
anneal
sirna
strand
quantif
sirna
duplex
soak
organ
doublestrand
sirna
protocol
follow
protozoan
parasit
entamoeba
histolytica
soli
schistosom
ndegwa
et
al
model
et
al
complet
cdna
sequenc
nt
carb
filament
fungu
aspergillu
nidulan
nm
nm
nm
nm
sirna
use
growth
inhibit
observ
respect
along
reduct
germ
tube
length
follow
treatment
nm
sirnatr
sampl
khatri
rajam
amarzguioui
et
al
soak
method
result
transient
express
make
less
potent
direct
microinject
scheper
therefor
effici
target
fungal
thick
cell
wall
consist
much
signific
soak
method
transient
rnai
limit
term
durat
experiment
variabl
rnai
effect
express
invert
repeat
ir
transgen
transgen
rnai
shown
induc
stabl
rnai
fungi
liu
et
al
howev
variabl
often
observ
gene
silenc
effect
dsrnaproduc
transgen
depend
target
gene
type
construct
site
integr
transgen
copi
number
irt
construct
use
target
gene
sequenc
incorpor
organismspecif
plasmid
plasmid
contain
irt
transform
organ
upon
transcript
form
hairpin
loop
cleav
endogen
dicer
gener
sirna
gener
small
interf
rna
sirna
cleav
endogen
mrna
help
risc
consid
sever
hairpinexpress
rna
system
avail
robust
rna
silenc
use
tissuespecif
rna
pol
ii
promot
tissuespecif
express
dsrna
hairpin
rna
assur
effici
format
dsrna
frequent
use
method
induct
rna
silenc
paddison
vogt
one
type
irt
longhairpin
rna
lhrna
gener
consist
bp
open
read
frame
spacer
approxim
oligonucleotid
invert
repeat
gene
sequenc
irt
construct
insert
plasmid
specif
particular
fungu
transform
respect
fungi
either
protoplast
format
electropor
transformationclon
effici
long
invert
repeat
cdna
low
select
process
timeconsum
construct
lhrna
difficult
involv
sever
round
pcr
clone
step
moreov
necessari
vector
plasmid
avail
speci
carri
sirna
deliveri
gener
longer
size
spacer
help
easi
clone
invert
repeat
improv
effici
rnai
use
ir
construct
contain
short
spacer
bp
middl
invert
repeat
improv
clone
effici
yu
et
al
moreov
presenc
intron
spacer
construct
also
improv
effect
enhanc
clone
effici
wesley
et
al
kalida
smith
nevertheless
strategi
success
use
trigger
silenc
variou
fungal
system
like
bipolari
oryza
moriwaki
et
al
irt
construct
consist
sens
antisens
polyketid
synthas
gene
bp
encod
melanin
product
separ
spacer
cutinas
gene
intron
obtain
studi
magnaporth
oryza
kadotani
et
al
yield
melanindefici
white
phenotyp
transform
anoth
studi
report
transform
xlnr
encod
xylanas
cellulas
niger
oliveira
et
al
show
decreas
activ
compar
control
strain
reason
attribut
either
rearrang
silenc
construct
appar
decreas
xylanolyt
activ
may
absenc
true
cotransform
anoth
promin
irt
success
use
mammalian
system
shorthairpin
rna
shrna
consist
bp
sirna
sens
antisens
sequenc
separ
spacer
nucleotid
sirna
sequenc
homolog
target
mrna
shrna
express
vector
avail
mammalian
system
requir
rna
polymeras
iii
system
shown
fig
preliminari
way
investig
knockdown
gene
percentag
silenc
fungu
measur
myceli
growth
fungu
either
coloni
diamet
method
myceli
dri
weight
method
radial
growth
assay
blot
techniqu
fluoresc
imag
biochem
assay
confirmatori
test
use
analyz
silenc
rna
protein
level
studi
carri
kadotani
et
al
blast
fungu
oryza
holen
investig
rna
silenc
use
enhanc
green
fluoresc
protein
egfp
sensesens
antisenseantisens
senseantisens
irt
construct
egfp
separ
partial
sequenc
gene
intern
spacer
employ
signific
silenc
induc
senseantisens
irt
construct
detect
loss
gfp
fluoresc
use
imag
analyz
sever
studi
employ
northern
blot
analysi
studi
gene
silenc
variou
fungi
yamada
et
al
kadotani
et
al
hammond
et
al
hammond
et
al
hammond
keller
seger
et
al
janu
et
al
captur
fluoresc
imag
plasmid
irt
contain
fluoresc
tag
like
gfp
seger
et
al
janu
et
al
assist
better
understand
protein
local
confirm
presenc
plasmid
cell
also
facilit
differenti
silenc
nonsilenc
transform
realtim
pcr
revers
transcript
pcr
khatri
rajam
oliveira
et
al
janu
et
al
liu
et
al
setup
also
employ
use
appropri
genespecif
primer
detect
quantifi
gene
transcript
level
liu
et
al
conduct
studi
liu
et
al
rna
silenc
pathogen
fungu
cryptococcu
neoforman
construct
irt
gene
relat
capsul
synthesi
adenin
biosynthesi
pathway
observ
reduct
gene
express
impart
transform
dull
pink
coloni
respect
silenc
analyz
employ
revers
transcript
pcr
genespecif
primer
pcr
product
stain
sybr
green
nucleic
acid
gel
stain
analysi
dnaassoci
fluoresc
janu
et
al
investig
report
system
dsred
identifi
silenc
transform
cosilenc
dsred
protein
isopenicillin
n
synthas
pcbc
involv
cephalosporin
c
biosynthesi
filament
fungu
acremonium
chrysogenum
employ
immunoblot
use
polyclon
antibodi
isopenicillin
n
synthas
assess
downregul
pcbc
gene
janu
et
al
biochem
assay
perform
well
specif
enzymeprotein
interest
evalu
silenc
target
protein
specif
sirna
hammond
keller
execut
norsolorin
acid
analysi
thinlay
chromatographi
observ
whether
nidulan
aflr
irt
suppress
product
hammond
keller
research
discoveri
vitro
need
accompani
establish
potenti
sirna
therapeut
antifung
drug
dosag
within
therapeut
window
test
determin
anim
model
mostli
murin
model
ibrahim
et
al
b
fungal
diseas
like
zygomycosi
aspergillosi
candidiasi
cryptococcosi
pharmacolog
studi
yet
conduct
anim
model
employ
sirna
therapi
fungal
infect
thu
dedic
effort
need
assess
sirna
therapi
mycos
variou
anim
model
investig
human
clinic
trial
rnai
explor
fungi
postgenom
era
understand
rna
silenc
machineri
also
tool
treat
fungal
diseas
effect
manag
convent
drug
instanc
past
decad
seen
rise
opportunist
invas
fungal
infect
mycos
due
signific
increas
popul
immunocompromis
patient
limit
exist
antifung
therapi
provid
impetu
toward
explor
rnai
therapeut
option
n
crassa
organ
first
rnai
gene
discov
succeed
numer
vitro
studi
achiev
improv
silenc
fungi
promis
rnai
therapeut
tool
identif
potenti
target
gene
necessit
sirna
design
silico
recent
wholegenom
studi
fungi
greatli
expedit
novel
drug
discoveri
process
even
though
rnairel
research
discoveri
made
rapid
progress
vitro
vivo
clinic
trial
neurodegen
diseas
cancer
proper
pharmacokinet
paramet
safeti
efficaci
rnai
still
remain
answer
mycos
rnai
therapeut
approach
rel
nascent
stage
uninterrupt
probe
prove
use
drive
prefer
option
treatment
mycos
long
run
